ArticleDiving and hyperbaric medicine2025
Novel use of hyperbaric oxygen treatment for treatment-resistant disseminated Saksenaea and Fusarium in a patient on extracorporeal membrane oxygenation (ECMO): a case report.
Article in Diving and hyperbaric medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Quantifying discrepancy between indicated and actual oxygen flow rates delivered by Comweld Ezi-flow low and standard flowmeters under hyperbaric conditions: a technical report.Diving and hyperbaric medicine · 2026Article
- Technical feasibility of hyperbaric oxygen therapy for gas embolism with ECMO support: a brief report.Critical care (London, England) · 2026Article
- Validation and clinical use of the Maquet (Getinge) original series Rotaflow extracorporeal membrane oxygenation device in hyperbaric conditions: a technical report.Diving and hyperbaric medicine · 2025Article
- The process, logistics and governance behind a high-stakes novel intervention: the use of extracorporeal membrane oxygenation (ECMO) in the hyperbaric chamber.Diving and hyperbaric medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Filamentous soil moulds such as Saksenaea and Fusarium are angioinvasive fungi responsible for severe disseminated infections. Saksenaea causes zygomycosis, with disseminated cases having over ninety percent mortality. Fusarium, a hyphomycetes mould, can also cause disseminated infections in immunocompromised individuals, with high mortality. We describe the case of a normally healthy 20-year-old male who survived major traumatic injuries resulting from an aviation incident. He subsequently developed disseminated cutaneous zygomycetes (Saksenaea) and Fusarium infection with associated immunosuppression, multiorgan dysfunction and sepsis. Treatment strategies included repeated and extensive surgical debridement (inferior orbital region to carotid sheath in the neck, to a depth of buccal mucosa and zygomatic bone in the cheek), antifungal agents including intravenous (IV) liposomal amphotericin B and voriconazole, and IV immunoglobulin and granulocyte colony stimulating factor. Despite maximal medical and surgical treatment, disease control was not achieved. After multi-specialty consensus that current management had failed to control the disease process, hyperbaric oxygen treatment (HBOT) was added to standard therapy on an experimental basis based on several case reports, pathophysiological rationale, and institutional experience with angioinvasive Mucor. The patient was on venovenous extracorporeal membrane oxygenation for all HBOT sessions; details are reported separately. Thirteen treatment sessions (243 kPa [2.4 atmospheres absolute], 95 min) were successfully delivered. Local and systemic disease control was achieved within several days of commencing HBOT, and after a prolonged period of rehabilitation and reconstruction, the patient was discharged home. We conclude that HBOT may have an important role in the management of angioinvasive fungal disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.